[1] Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet, 2021,397(10290):2212-2224.
[2] Prasun P. Mitochondrial dysfunction in metabolic syndrome. Biochim Biophys Acta Mol Basis Dis, 2020,1866(10):165838.
[3] Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab, 2020,42:101092.
[4] Zhou J, Zhou F, Wang W,et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology, 2020,71(5):1851-1864.
[5] Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 2020,158(7):1999-2014.e1.
[6] Tilg H, Adolph TE, Dudek M, et al. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab, 2021,3(12):1596-1607.
[7] 徐梓馨, 罗声政, 徐铭益. 线粒体功能异常在非酒精性脂肪性肝病发生中的机制. 临床肝胆病杂志, 2020, 36(10): 2353-2355.
[8] CHEN H. Nutrient mTORC1 signaling contributes to hepatic lipid metabolism in the pathogenesis of non-alcoholic fatty liver disease. Liver Research, 2020, 4(1): 15-22.
[9] Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci,2018,75(18):3313-3327.
[10] 陈芮莹, 林以宁. 肝脏脂质代谢在非酒精性脂肪性肝病发生发展中的生物学机制. 江西医药, 2021, 56(3): 399-401.
[11] Smith GI, Shankaran M, Yoshino M,et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest, 2020,130(3):1453-1460.
[12] Rada P, González-Rodríguez Á, García-Monzón C, et al. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell Death Dis, 2020,11(9):802.
[13] Bence KK, Birnbaum MJ. Metabolic drivers of non-alcoholic fatty liver disease. Mol Metab, 2021,50:101143.
[14] 陈轶妍, 陆炎. 被中饱私囊的脂肪——非酒精性脂肪性肝病. 自然杂志, 2019, 41(6): 414-422.
[15] Montaigne D, Butruille L, Staels B. PPAR control of metabolism and cardiovascular functions. Nat Rev Cardiol, 2021,18(12):809-823.
[16] Tahri-Joutey M, Andreoletti P, Surapureddi S,et al. Mechanisms mediating the regulation of peroxisomal fatty acid beta-oxidation by PPARα. Int J Mol Sci, 2021,22(16):8969.
[17] Heeren J, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab, 2021,50:101238.
[18] Di Ciaula A, Calamita G, Shanmugam H,et al. Mitochondria matter: systemic aspects of nonalcoholic fatty liver disease (NAFLD) and diagnostic assessment of liver function by stable isotope dynamic breath tests. Int J Mol Sci, 2021,22(14):7702.
[19] 邵幼林, 范建高. 非酒精性脂肪性肝病患者肝脏脂肪的来源与去路. 国际消化病杂志, 2019, 39(5): 316-320.
[20] Soto-Avellaneda A, Morrison BE. Signaling and other functions of lipids in autophagy: a review. Lipids Health Dis, 2020,19(1):214.
[21] 周振华, 王灵台, 高月求. 肝细胞线粒体自噬在非酒精性脂肪性肝病发病机制中的作用. 临床肝胆病杂志, 2019, 35(12): 2809-2811.
[22] Cunningham RP, Moore MP, Dashek RJ,et al. Critical role for hepatocyte-specific eNOS in NAFLD and NASH. Diabetes, 2021,70(11):2476-2491.
[23] Zhou T, Chang L, Luo Y, et al. Corrigendum to “Mst1 inhibition attenuates non-alcoholic fatty liver disease via reversing Parkin-related mitophagy”[Redox Biol. 21 (2019 Feb) 101120]. Redox Biol, 2020,28:101299.
[24] Chen L, Li Y, Sottas C,et al. Loss of mitochondrial ATPase ATAD3A contributes to nonalcoholic fatty liver disease through accumulation of lipids and damaged mitochondria. J Biol Chem, 2022,298(6):102008.
[25] Dabravolski SA, Bezsonov EE, Orekhov AN. The role of mitochondria dysfunction and hepatic senescence in NAFLD development and progression. Biomed Pharmacother. 2021,142:112041.
[26] Natarajan V, Chawla R, Mah T,et al. Mitochondrial dysfunction in age-related metabolic disorders. Proteomics, 2020,20(5-6):e1800404.
[27] Lin H, Yip TC, Zhang X, et al. Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease. Hepatology, 2023,77(2):573-584.
[28] Ribas GS, Vargas CR. Evidence that oxidative disbalance and mitochondrial dysfunction are involved in the pathophysiology of fatty acid oxidation disorders. Cell Mol Neurobiol, 2022,42(3):521-532.
[29] Ma X, Qian H, Chen A, et al. Perspectives on mitochondria-ER and mitochondria-lipid droplet contact in hepatocytes and hepatic lipid metabolism. Cells, 2021,10(9):2273.
[30] Kang SWS, Cogger VC, Le Couteur DG, et al. Multiple cellular pathways regulate lipid droplet homeostasis for the establishment of polarity in collagen sandwich-cultured hepatocytes. Am J Physiol Cell Physiol, 2019,317(5):C942-C952.
[31] Kim YS, Nam HJ, Han CY, et al. Liver X receptor alpha activation inhibits autophagy and lipophagy in hepatocytes by dysregulating autophagy-related 4B cysteine peptidase and rab-8B, reducing mitochondrial fuel oxidation. Hepatology, 2021,73(4):1307-1326.
[32] Zheng Y, Qu H, Xiong X, et al. Deficiency of mitochondrial glycerol 3-phosphate dehydrogenase contributes to hepatic steatosis. Hepatology, 2019,70(1):84-97.
[33] Bima AI, Mahdi AS, Al Fayez FF,et al. Cellular senescence and vitamin D deficiency play a role in the pathogenesis of obesity-associated subclinical atherosclerosis: study of the potential protective role of vitamin D supplementation. Cells, 2021,10(4):920.
[34] Wu S, Zou MH. AMPK, mitochondrial function, and cardiovascular disease. Int J Mol Sci, 2020,21(14):4987.
[35] 黄劲, 苏连杰, 冯杰, 等. 中药单体调控AMPK通路防治NAFLD的研究进展. 中国实验方剂学杂志, 2023, 29(4): 1-12.
[36] Zhou H, Ma C, Wang C, et al. Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease. Eur J Pharmacol, 2021,898:173976.
[37] Wu L, Mo W, Feng J, et al. Astaxanthin attenuates hepatic damage and mitochondrial dysfunction in non-alcoholic fatty liver disease by up-regulating the FGF21/PGC-1α pathway. Br J Pharmacol, 2020,177(16):3760-3777.
[38] Mu JK, Zi L, Li YQ, et al. Jiuzhuan Huangjing Pills relieve mitochondrial dysfunction and attenuate high-fat diet-induced metabolic dysfunction-associated fatty liver disease. Biomed Pharmacother, 2021,142:112092.
[39] Xie C, Halegoua-DeMarzio D. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter? Nutrients, 2019,11(11):2837.
[40] Che W, Zhao M, Li X, et al. Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment. Front Endocrinol (Lausanne), 2022,13:1002916. |
